Background

This clinical trial evaluates whether early intensive antiretroviral therapy (ART) combined with broadly neutralizing antibodies (bNAb) can suppress viral levels below the limit of detection in infants infected with HIV. The objective is to elucidate the impact of early treatment on the immune system and to block viral reservoirs during the neonatal immune development stage.

Treatment Strategy and Mechanism

Early intensive ART employs higher drug concentrations and combination regimens than standard therapy to maximally suppress viral replication. Adding bNAb directly neutralizes viral envelope proteins, increasing the likelihood of eliminating residual low‑level virus. As an antibody‑based therapy, bNAb reduces the risk of resistance to viral mutations and supports the immune system.

Current Treatment Landscape and Differentiation

Current infant HIV treatment initiates ART within weeks of birth, but most regimens remain low‑dose monotherapy or dual therapy, making complete viral suppression challenging. While standard therapy can achieve viral control, it rarely attains full remission and carries risks of long‑term drug toxicity and resistance. This study differentiates itself by testing whether early high‑intensity therapy combined with bNAb can achieve full remission beyond existing approaches.

Potential Impact of Success

If complete HIV remission is demonstrated in infants, it could reduce treatment costs and improve quality of life for hundreds of thousands of infected children worldwide. Moreover, a strategy that fundamentally blocks viral reservoirs would provide critical scientific rationale for vaccine development and cure research. Pharmaceutical and biotech companies would gain opportunities to expand product pipelines based on bNAb technology, and investors may consider portfolio reallocation toward this modality.

Challenges and Timeline Outlook

The study is still in the enrollment phase and, as a Phase 1/2 trial, the primary challenges are securing safety and early efficacy data. Ongoing monitoring of long‑term adverse events associated with early treatment and sustained efficacy of bNAb are required. Although a definitive study completion date has not been set, Phase 2 trials typically generate primary outcomes within 2–3 years.